Available in the shop
- Cagrilintide 5 mg — $210.00
- Cagrilintide 5 mg + Semaglutide 5 mg — $329.70
- Cagrilintide 10 mg — $399.00
Sold for in vitro laboratory research only — not for human or animal consumption. ≥99% purity specification.
Identification
| Field of research | Weight research |
|---|---|
| Formula | C194H312N54O59S2 |
| Molecular weight | 4409 g/mol |
| CAS number | 1415456-99-3 |
| Also known as | Cagrilintide [INN], RefChem:573322, AO43BIF1U8, GTPL13768, LDERDVMBIYGIOI-IZVMHKDJSA-N, EX-A10092, AT42613, analogue 23 [PMID: 34288673], NN0174-0833 |
| PubChem | CID 171397054 |
Summary
Cagrilintide is a long-acting analogue of amylin.
From Wikipedia, available under CC BY-SA 4.0. Short description from Wikidata (CC0).
Published research
Titles are shown as published. Listing a paper is not an endorsement of its findings, and many papers on research peptides are laboratory or animal studies: the type of study is shown when PubMed records it.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityRandomized Controlled TrialMulticenter StudyClinical Trial, Phase IIIGarvey WT, Blüher M, Osorto Contreras CK et al. · N Engl J Med, 2025 · PMID 40544433 · DOI
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysisSystematic ReviewNetwork Meta-AnalysisYao H, Zhang A, Li D et al. · BMJ, 2024 · PMID 38286487 · DOI
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 DiabetesRandomized Controlled TrialClinical Trial, Phase IIIMulticenter StudyDavies MJ, Bajaj HS, Broholm C et al. · N Engl J Med, 2025 · PMID 40544432 · DOI
- Weight management treatment in obesityReviewRubio-Herrera MA, Mera-Carreiro S · Med Clin (Barc), 2025 · PMID 40865172 · DOI
- Beyond weight loss: multisystem benefits of obesity medicationsReviewSavas M, Kuckuck S, Boon MR et al. · Lancet Diabetes Endocrinol, 2026 · PMID 42208956 · DOI
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trialClinical Trial, Phase IIMulticenter StudyRandomized Controlled TrialLau DCW, Erichsen L, Francisco AM et al. · Lancet, 2021 · PMID 34798060 · DOI
- Novel GLP-1-based Medications for Type 2 Diabetes and ObesityReviewSon JW, le Roux CW, Blüher M et al. · Endocr Rev, 2026 · PMID 41054801 · DOI
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trialRandomized Controlled TrialMulticenter StudyClinical Trial, Phase IIResearch Support, Non-U.S. Gov'tFrias JP, Deenadayalan S, Erichsen L et al. · Lancet, 2023 · PMID 37364590 · DOI
Top 8 of 102 results, by relevance. See all on PubMed.
Search query "Cagrilintide"[Title/Abstract]
Data provenance
| Data | Source | Record |
|---|---|---|
| Chemical identity and structure | PubChem | CID 171397054 |
| Published literature | PubMed | Search on PubMed |
| Summary sentence | Wikipedia | Cagrilintide |
Data retrieved 2026-10-08. See About for the sources. How the data is collected and checked: Methods.